0I3Q Stock Overview
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Corcept Therapeutics Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.00 |
| 52 Week High | US$34.13 |
| 52 Week Low | US$20.88 |
| Beta | 0.48 |
| 1 Month Change | 1.08% |
| 3 Month Change | -7.50% |
| 1 Year Change | 2.56% |
| 3 Year Change | 1.97% |
| 5 Year Change | 90.99% |
| Change since IPO | -8.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0I3Q | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -5.8% | 3.0% | 0.3% |
| 1Y | 2.6% | -2.8% | -0.8% |
Return vs Industry: 0I3Q exceeded the UK Pharmaceuticals industry which returned -2.6% over the past year.
Return vs Market: 0I3Q exceeded the UK Market which returned -0.3% over the past year.
Price Volatility
| 0I3Q volatility | |
|---|---|
| 0I3Q Average Weekly Movement | 6.3% |
| Pharmaceuticals Industry Average Movement | 8.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0I3Q has not had significant price volatility in the past 3 months.
Volatility Over Time: 0I3Q's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 352 | Joseph Belanoff | www.corcept.com |
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing’s syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors.
Corcept Therapeutics Incorporated Fundamentals Summary
| 0I3Q fundamental statistics | |
|---|---|
| Market cap | US$2.44b |
| Earnings (TTM) | US$105.50m |
| Revenue (TTM) | US$482.38m |
22.8x
P/E Ratio5.0x
P/S RatioIs 0I3Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0I3Q income statement (TTM) | |
|---|---|
| Revenue | US$482.38m |
| Cost of Revenue | US$6.48m |
| Gross Profit | US$475.89m |
| Other Expenses | US$370.40m |
| Earnings | US$105.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.02 |
| Gross Margin | 98.66% |
| Net Profit Margin | 21.87% |
| Debt/Equity Ratio | 0% |
How did 0I3Q perform over the long term?
See historical performance and comparison